PL3003285T3 - Stała farmaceutyczna postać dawkowania do uwalniania co najmniej dwóch substancji czynnych w jamie ustnej - Google Patents

Stała farmaceutyczna postać dawkowania do uwalniania co najmniej dwóch substancji czynnych w jamie ustnej

Info

Publication number
PL3003285T3
PL3003285T3 PL14808018T PL14808018T PL3003285T3 PL 3003285 T3 PL3003285 T3 PL 3003285T3 PL 14808018 T PL14808018 T PL 14808018T PL 14808018 T PL14808018 T PL 14808018T PL 3003285 T3 PL3003285 T3 PL 3003285T3
Authority
PL
Poland
Prior art keywords
release
dosage form
oral cavity
pharmaceutical dosage
active pharmaceutical
Prior art date
Application number
PL14808018T
Other languages
English (en)
Inventor
Andreas Hugerth
Katarina Lindell
Fredrik Nicklasson
Kristina Thyresson
Original Assignee
Mcneil Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mcneil Ab filed Critical Mcneil Ab
Publication of PL3003285T3 publication Critical patent/PL3003285T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
PL14808018T 2013-06-03 2014-06-02 Stała farmaceutyczna postać dawkowania do uwalniania co najmniej dwóch substancji czynnych w jamie ustnej PL3003285T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1300404 2013-06-03
PCT/SE2014/050670 WO2014196916A1 (en) 2013-06-03 2014-06-02 Solid pharmaceutical dosage form for release of at least one active pharmaceutical ingredient in the oral cavity
EP14808018.7A EP3003285B1 (en) 2013-06-03 2014-06-02 Solid pharmaceutical dosage form for release of at least two active pharmaceutical ingredients in the oral cavity

Publications (1)

Publication Number Publication Date
PL3003285T3 true PL3003285T3 (pl) 2022-06-20

Family

ID=52008428

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14808018T PL3003285T3 (pl) 2013-06-03 2014-06-02 Stała farmaceutyczna postać dawkowania do uwalniania co najmniej dwóch substancji czynnych w jamie ustnej

Country Status (13)

Country Link
US (2) US20160095818A1 (pl)
EP (1) EP3003285B1 (pl)
CN (1) CN105307645A (pl)
AU (1) AU2014275543B2 (pl)
BR (1) BR112015030140A2 (pl)
CA (1) CA2914379C (pl)
DK (1) DK3003285T3 (pl)
ES (1) ES2908977T3 (pl)
HK (1) HK1218884A1 (pl)
PL (1) PL3003285T3 (pl)
PT (1) PT3003285T (pl)
RU (1) RU2015156033A (pl)
WO (1) WO2014196916A1 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9993558B2 (en) 2004-10-01 2018-06-12 Ramscor, Inc. Sustained release eye drop formulations
CN110339153A (zh) 2013-05-24 2019-10-18 爱康生物科技有限公司 地塞米松单位剂型、试剂盒及白内障手术后炎症中的应用
US9855227B2 (en) 2015-12-18 2018-01-02 The Procter & Gamble Company Quick dissolving diphenhydramine oral dosage form
CN105833278B (zh) * 2016-04-25 2018-05-08 北京嘉安医疗器械科技有限公司 用于治疗口腔干燥和口腔疾病的组合物
CN105919982A (zh) * 2016-06-30 2016-09-07 合肥华方医药科技有限公司 一种消旋卡多曲口腔速溶膜及其制备方法
AU2018216886B2 (en) 2017-02-01 2023-02-23 Johnson & Johnson Consumer Inc. A lozenge
ES2975449T3 (es) 2017-05-22 2024-07-05 Johnson & Johnson Consumer Inc Forma farmacéutica de pastilla
RU2749902C2 (ru) * 2018-10-31 2021-06-18 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция для лечения инфекционно-воспалительных заболеваний
US11179331B1 (en) 2020-04-21 2021-11-23 Cure Pharmaceutcai Holding Corp Oral soluble film containing sildenafil citrate
MX2022015719A (es) 2020-06-15 2023-01-24 Unilever Ip Holdings B V Una composicion antimicrobiana para combatir el mal olor.
CN113413388B (zh) * 2021-06-30 2022-11-15 上海奥全生物医药科技有限公司 含有枸橼酸西地那非的药物组合物、制备方法及其应用
WO2023028179A1 (en) * 2021-08-25 2023-03-02 Get-Grin Inc. Systems and methods for monitoring a tooth whitening regimen

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE8310750U1 (de) 1983-04-12 1984-07-19 Geppert, Helmut, 5162 Niederzier Spannvorrichtung fuer einen ueber einen eine treibwalze antreibenden getriebemotor angetriebenen bandfoerderer
US4678516A (en) * 1984-10-09 1987-07-07 The Dow Chemical Company Sustained release dosage form based on highly plasticized cellulose ether gels
US5002769A (en) * 1987-03-13 1991-03-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for the sustained-release of chlorhexidine
GB8928196D0 (en) * 1989-12-13 1990-02-14 Merrell Dow Pharmaceuticals Li Pharmaceutical lozenges
US5098715A (en) * 1990-12-20 1992-03-24 Burroughs Wellcome Co. Flavored film-coated tablet
US5614207A (en) * 1995-06-30 1997-03-25 Mcneil-Ppc, Inc. Dry mouth lozenge
AU733140B2 (en) * 1998-09-29 2001-05-10 Hitachi Limited A friction stir welding method
US20020119196A1 (en) * 2000-12-21 2002-08-29 Narendra Parikh Texture masked particles containing an active ingredient
US8980334B2 (en) 2001-02-28 2015-03-17 Axiomedic Ltd. Double-layered absorbable solid compositions for the topical treatment of oral mucosal disorders
US6596313B2 (en) * 2001-08-06 2003-07-22 The Quigley Corporation Nutritional supplement and methods of using it
EP1656117A1 (en) 2003-08-11 2006-05-17 Merck Frosst Canada Ltd. Flavored taste-masked pharmaceutical formulation made using a one-step coating process
GB0330255D0 (en) * 2003-12-31 2004-02-04 Vectura Ltd Multiparticulate formulations for oral delivery
US20070196474A1 (en) * 2004-04-30 2007-08-23 Withiam Michael C Rapidly disintegrating low friability tablets comprising calcium carbonate
US8238554B2 (en) * 2004-07-22 2012-08-07 Sanyo Electric Co., Ltd. Method for transmission/reception of contents usage right information in encrypted form, and device thereof
DE102004041850A1 (de) 2004-08-27 2006-03-02 Basf Ag Verfahren zur Herstellung von C5-Aldehyden und Propen aus einem 1-Buten- und 2-Buten-haltigen C4-Strom
US8323683B2 (en) * 2005-05-18 2012-12-04 Mcneil-Ppc, Inc. Flavoring of drug-containing chewing gums
WO2007046890A1 (en) * 2005-10-14 2007-04-26 Effrx, Inc. Lozenge for treatment of dry mouth and related conditions
MX2008012299A (es) * 2006-03-31 2008-11-18 Rubicon Res Private Ltd Tabletas de desintegracion oral.
US20080031927A1 (en) * 2006-07-11 2008-02-07 Catani Steven J Solid oral dosage vitamin and mineral compositions
US20100247453A1 (en) * 2006-07-12 2010-09-30 Thomas L. Jones Composition and method of treating a sore throat
WO2009078034A2 (en) * 2007-11-26 2009-06-25 Rubicon Research Private Limited Oral disintegrating tablets of ropinirole hydrochloride
CA2708152A1 (en) * 2007-12-10 2009-06-18 Eurand, Inc Orally disintegrating tablets comprising diphenhydramine
WO2009078037A2 (en) * 2007-12-17 2009-06-25 Gland Pharma Limited Novel process for the preparation of iron sucrose complex
US20100028512A1 (en) * 2008-03-28 2010-02-04 The Coca-Cola Company Bio-based polyethylene terephthalate packaging and method of making thereof
WO2010046933A2 (en) * 2008-10-22 2010-04-29 Rubicon Research Private Limited Pharmaceutical compositions of taste-masked linezolid
WO2011030351A2 (en) * 2009-09-03 2011-03-17 Rubicon Research Private Limited Taste - masked pharmaceutical compositions
US9012384B2 (en) * 2010-07-30 2015-04-21 Chevron U.S.A. Inc. Method of preparing greases
US8715729B2 (en) * 2010-12-22 2014-05-06 Basf Se Rapidly disintegrating, solid coated dosage form
CN107252419A (zh) 2010-12-22 2017-10-17 巴斯夫欧洲公司 快速崩解的固体包衣剂型
US20120288591A1 (en) * 2011-05-13 2012-11-15 The Hershey Company Film coated confectionery product
KR20140048882A (ko) * 2011-05-13 2014-04-24 이모셔널 브레인 비.브이. 약물 전달 시스템
US20130177646A1 (en) * 2012-01-05 2013-07-11 Mcneil Ab Solid Nicotine-Comprising Dosage Form with Reduced Organoleptic Disturbance

Also Published As

Publication number Publication date
WO2014196916A1 (en) 2014-12-11
CA2914379C (en) 2021-03-23
RU2015156033A3 (pl) 2018-05-03
CA2914379A1 (en) 2014-12-11
BR112015030140A2 (pt) 2017-07-25
EP3003285A4 (en) 2016-11-23
AU2014275543B2 (en) 2019-09-12
AU2014275543A1 (en) 2015-12-10
HK1218884A1 (zh) 2017-03-17
PT3003285T (pt) 2022-05-02
EP3003285B1 (en) 2022-02-16
US20160095818A1 (en) 2016-04-07
EP3003285A1 (en) 2016-04-13
US20180338924A1 (en) 2018-11-29
CN105307645A (zh) 2016-02-03
DK3003285T3 (en) 2022-04-04
RU2015156033A (ru) 2017-07-13
ES2908977T3 (es) 2022-05-04

Similar Documents

Publication Publication Date Title
IL283032A (en) Preparations for oral administration of tofacitinib
PL3003285T3 (pl) Stała farmaceutyczna postać dawkowania do uwalniania co najmniej dwóch substancji czynnych w jamie ustnej
ZA201509239B (en) Amorphous letermovir and solid pharmaceutical formulations thereof for oral administration
HUE040666T2 (hu) Ibandronsavat vagy gyógyászatilag elfogadható sóját és D vitamint tartalmazó, orális beadásra alkalmas szilárd kompozíció
IL239958A (en) A chewable oral preparation and process for preparing it
IL240666A0 (en) Pharmaceutical preparations for oral administration and their uses
PT3318259T (pt) Composição farmacêutica estável para administração oral
ZA201505084B (en) Monolithic dosage form for the modified release of an active ingredient combination
ZA201604100B (en) Gastro-retentive oral pharmaceutical compositions
SMT201900538T1 (it) Forme di dosaggio per la somministrazione orale di sostanze attive
EP2979698A4 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION
HUE047749T2 (hu) Gyógyszereket alacsony dózisban tartalmazó gyógyászati készítmények